重要的外卖stelix药品报告说，美国食品药品管理局批准了其代理前列腺癌筛查的代理。Gozellix用于针对患有阳性前列腺癌病变的男性进行PET扫描测试，而那些可能会复发该疾病的人。 (TLX) rose 6% Friday as the U.S. Food and Drug Administration (FDA) approved the biopharma firm's agent for use in tests to screen for prostate cancer.

Telix explained that the drug, Gozellix, is indicated for Positron Emission Tomography (PET) scanning of Prostate-Specific Membrane Antigen (PSMA) "positive lesions in men with prostate cancer who have suspected metastasis并且是初始确定治疗的候选人。”它也是为基于升高的血清前列腺规范的怀疑复发的人设计的IC抗原（PSA）水平。  

The company explained that Gozellix has a longer shelf life than gallium-based imaging products currently on the market, "bringing the accuracy and clinical utility of gallium-based imaging to more patients across the U.S."

Kevin Richardson, CEO of Telix Precision Medicine, called the FDA decision "a major win for prostate cancer patients."

Telix Pharmaceutical shares only began 11月的美国交易，此后增长了20％以上。